Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 13,625 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: bendamustine, erlotinib, Maintenance erlotinib; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Depression, Weight Changes
Interventions: Calcium-Rich Diet, Arm 2: Exercise + Calcium-Rich Diet, Exercise + Fruit & Vegetable, Low Fat + Calcium Diet; Dietary Supplement · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Durham, North Carolina • Goldsboro, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: Psoriatic Arthritis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, incomplete Freund's adjuvant; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Psoriasis
Interventions: Methotrexate, Adalimumab (Humira); Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Computed Tomography; Radiation
Lead sponsor: Koning Corporation; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Metastatic Melanoma
Interventions: Vinorelbine, Docetaxel, Sargramostim; Drug
Lead sponsor: John P. Fruehauf; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Cancer
Interventions: allogeneic large multivalent immunogen breast cancer vaccine, aldesleukin; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Scleroderma, Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream; Drug
Lead sponsor: Prasco LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Denver, Colorado + 23 more

Conditions: Breast Cancer
Interventions: CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique; Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Cisplatin, Rucaparib; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 27
States / cities: Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more

Conditions: Androgenic Alopecia, Alopecia, Baldness
Interventions: Autologous Hair Follicle-Derived Secretome, Placebo Control; Other
Lead sponsor: Acorn Biolabs Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Hollywood, California

Conditions: Raynaud
Interventions: Tadalafil; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia
Interventions: "Who is Luke Eemia?" Storybook; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 3 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lynch Syndrome, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Family Characteristics, Genetic Predisposition
Interventions: online cancer risk assessment, Usual care; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 25 Years to 75 Years
Enrollment: 18,623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Oakland, California

Conditions: Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
Interventions: Indocyanine Green; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Active Dermatomyositis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 3 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
Interventions: Proactive Psychiatry Consultation (PPC); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers; Drug · Device
Lead sponsor: Boston University; Other
Eligibility: 3 Months to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alopecia Areata
Interventions: Abatacept; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: FB825, Placebo; Biological · Other
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Beverly Hills, California • Encino, California • Huntington Beach, California + 13 more

Search by objective public record fields.

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Survival TRaining for ENhancing Total Health (STRENGTH)

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Inflammation-Induced CNS Glutamate During Breast Cancer Treatment

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Mechanism of Action Study for Psoriasis

Cone Beam Computed Tomography for Breast Imaging

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

Tadalafil for the Treatment of Raynaud's

Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.

Family History Study on Cancer Risk

Intraoperative Imaging of Breast Cancer With Indocyanine Green

Safety and Efficacy of BAF312 in Dermatomyositis

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis